Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06819228 · ClinicalTrials.gov registry record · Early Phase 1
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
A Early Phase 1 study of HNSCC and SCC - Squamous Cell Carcinoma, sponsored by Vanderbilt-Ingram Cancer Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT06819228 is a Early Phase 1 study of HNSCC and SCC - Squamous Cell Carcinoma that is actively recruiting participants, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 18 participants, below the 190-participant average among 23 other HNSCC trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06819228, a Early Phase 1 study of HNSCC and SCC - Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Vanderbilt-Ingram Cancer Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is exploring the use of Panitumumab in Head and Neck Cancer. Panitumumab is an approved drug named Vectibix and is used as an anti-cancer agent in other cancers such as colorectal cancer. It works by attaching to the cancer cell in a unique way that allows the drug to get into the cancer tissue. In addition to the Panitumumab, participants will also receive a Panitumumab-IRDye800 (Pan800) or a fluorescently labeled Panitumumab infusion. IRDye800 is an investigational dye that, when tested in the lab, helps various characteristics of human tissue show up better when using a special camera during surgery. Panitumumab-IRDye800 is a combination of the drug and the dye that attaches to cancer cells and appears to make them visible to the doctor when he or she uses the special camera during surgery. The goal of this study is to use a novel and possibly safer approach to identify an optimal dose for panitumumab to treat cancer patients by using a new light-based therapy. In this study, different drug levels will be analyzed using this approach to understand how much drug reaches the tumor at different administered doses, which may help us provide safer and/or more effective therapies in the future. The goal is to identify the correct amount or dose of a drug that is needed for effective cancer therapies. Often, clinical studies look at how much of the drug can be tolerated before patients become sick, rather than how much of the drug is required to be effective. IRDye800 is an investigational dye that, when tested in the lab, helps various characteristics of human tissue show up better when using a special camera during surgery. Panitumumab-IRDye800 is a combination of the drug and the dye that attaches to cancer cells and appears to make them visible to the doctor when he or she uses the special camera during surgery. This will help the surgeon with clinical margins during surgery and will may have a clearer way to differentiate between cancer and healthy ti
Conditions Studied
Interventions
- DRUG Panitumumab IRDye 800
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-04-17 |
| Est. Completion | 2029-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06819228
The ClinicalTrials.gov registry entry for NCT06819228 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 190-participant average among 23 other HNSCC trials with a reported enrollment target (91% lower). The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with HNSCC appearing as the primary indexed condition, and to 1 intervention - of which Panitumumab IRDye 800 is the first listed.
NCT06819228 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT06819228 about?
NCT06819228 is a clinical study titled "Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer". This study is exploring the use of Panitumumab in Head and Neck Cancer. Panitumumab is an approved drug named Vectibix and is used as an anti-cancer agent in other cancers such as colorectal cancer. It works by attaching to the cancer cell in a unique way that allows the drug to get into the cancer ...
What is the current status of trial NCT06819228?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2025-04-17. Estimated completion is 2029-03.
What conditions does trial NCT06819228 study?
This clinical trial studies the following conditions: HNSCC, SCC - Squamous Cell Carcinoma, HNSCC,Larynx, Pharynx and Oral Cavity.
What interventions are being tested in trial NCT06819228?
The interventions under investigation include: Panitumumab IRDye 800 (DRUG).
Who is sponsoring clinical trial NCT06819228?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06819228 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HNSCC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
High-Resolution PET-CT Imaging for Surgical Margin Visualization
RECRUITING · NA
-
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.